|
|
Volumn 144, Issue 4, 2013, Pages 846-848
|
|
Ustekinumab for moderate-to-severe crohn's disease
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MESALAZINE;
PLACEBO;
USTEKINUMAB;
BASAL CELL CARCINOMA;
CATHETER INFECTION;
CLOSTRIDIUM DIFFICILE INFECTION;
CONTROLLED STUDY;
CROHN DISEASE;
CROHN DISEASE ACTIVITY INDEX;
DOUBLE BLIND PROCEDURE;
DRUG RESPONSE;
HUMAN;
INDUCTION CHEMOTHERAPY;
MAINTENANCE CHEMOTHERAPY;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
MULTIPLE SCLEROSIS;
NOTE;
PERIANAL ABSCESS;
PHASE 2 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PSORIASIS;
RANDOMIZED CONTROLLED TRIAL;
VIRAL GASTROENTERITIS;
|
|
EID: 84875241315
PISSN: 00165085
EISSN: 15280012
Source Type: Journal
DOI: 10.1053/j.gastro.2013.02.030 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
